DHA-clozapine (tentative trade name Clozaprexin)[1] is an atypical antipsychotic drug candidate that was created and originally tested by chemists at Protarga, a small pharmaceutical in Pennsylvania, and scientists at Harvard University.[2]
Clinical data | |
---|---|
Trade names | Clozaprexin |
Other names | Docosahexaenoyl clozapine |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C40H49ClN4O |
Molar mass | 637.31 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
It is a prodrug of clozapine; the fatty acid docosahexaenoic acid (DHA) was added to clozapine in order to increase penetration of the blood–brain barrier.[3]
Protarga was purchased by Luitpold Pharmaceuticals in 2003 and development was discontinued in 2007.[1]